LONDON (Reuters) - AstraZeneca is to buy U.S. company Ardea Biosciences for $1.26 billion, giving it a new gout drug to bolster a weak pipeline in a deal that feeds a wave of M&A in the biotechnology sector.
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/nOu0pEkO6O4/us-ardea-astrazeneca-idUSBRE83M07P20120423
best news online money internet business Current news latest news top news
No comments:
Post a Comment